News Agency
Men's Weekly

Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer

  • Written by PR Newswire
Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to Develop and Commercialize ORSERDU® (Elacestrant) in China to Address Advanced or Metastatic Breast Cancer
  • ORSERDU is the first treatment specifically approved for patients with ER+, HER2- advanced or metastatic breast cancer tumors that harbor ESR1 mutations, representing the first innovation in endocrine therapy in nearly 20 years.
  • ESR1 mutations are present in up to 40% of ER+, HER2- advanced or metastatic breast cancers, and are a known driver of...

Read more: Menarini Group and SciClone Pharmaceuticals Announce Exclusive Sub-Licensing Collaboration to...

Hard Chrome Plating: Enhancing Durability And Performance In Industrial Components

In industries where equipment is exposed to constant friction, pressure, and harsh operating conditions, surface protection becomes critical to performance and longevity. Hard chrome plating is a specialised surface treatment process widely used to improve wear resistance, reduce friction, and extend... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion